anti eno2 (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
94
Structured Review
Cell Signaling Technology Inc
anti eno2
Anti Eno2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 70 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+eno2/Enolase-2+Antibody/pmc12593089-107-117-118
Average 94 stars, based on 70 article reviews
Anti Eno2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 70 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+eno2/Enolase-2+Antibody/pmc12593089-107-117-118
Average 94 stars, based on 70 article reviews
anti eno2 - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Staining:Article Title: Long-Term Effects of Radiation Therapy on Cerebral Microvessel Proteome: A Six Month Post-Exposure Analysis Article Snippet: Equal amounts of protein (5–10 μg) from control and irradiated groups were separated on NuPAGE 4% to 12% Bis-Tris gels (Life Technologies) and transferred to polyvinylidene difluoride (PVDF) membranes using the Mini-PROTEAN 3 blotting system (Bio-Rad). .. Membranes were stained with Ponceau S (Cell Signaling #59803S) to confirm protein transfer, washed in TBS with Tween (TBST), and blocked with 3% BSA (RPI Research #9048–46–8) or Starting Block Blocking Buffer (Thermo Fisher Scientific #37538) for 2 h. Membranes were incubated overnight at 4 °C with primary antibodies, including anti-NDUFB8 (Abcam, no. ab110413), anti-NDUFA11 (ABclonal, no. A16239), anti-NDUFA4 (ABclonal, no. A15693), anti-SDHA (Cell Signaling, no. 11998), anti-SDHB (Abcam, no. ab110413), anti-UQCRC2 (Aviva systems biology, no. OAAN01132), anti-MT-CO2 (ABclonal, no. A11154), anti-COX6B1 (ABclonal, no. A2228), anti-ATP5F1C (ABclonal, no. A15257), anti-ATP6VID (ABclonal, no. A12940), anti-ATP5F1A (ABclonal, no. A11217), anti-ACLY (ABclonal, no. A3719), anti-IDH3A (ABclonal, no. A14650), anti-DLD (ABclonal, no. A13296), anti-ACO2 (ABclonal, no. A3716), anti-MDH2 (ABclonal, no. A13516), Blocking Assay:Article Title: Long-Term Effects of Radiation Therapy on Cerebral Microvessel Proteome: A Six Month Post-Exposure Analysis Article Snippet: Equal amounts of protein (5–10 μg) from control and irradiated groups were separated on NuPAGE 4% to 12% Bis-Tris gels (Life Technologies) and transferred to polyvinylidene difluoride (PVDF) membranes using the Mini-PROTEAN 3 blotting system (Bio-Rad). .. Membranes were stained with Ponceau S (Cell Signaling #59803S) to confirm protein transfer, washed in TBS with Tween (TBST), and blocked with 3% BSA (RPI Research #9048–46–8) or Starting Block Blocking Buffer (Thermo Fisher Scientific #37538) for 2 h. Membranes were incubated overnight at 4 °C with primary antibodies, including anti-NDUFB8 (Abcam, no. ab110413), anti-NDUFA11 (ABclonal, no. A16239), anti-NDUFA4 (ABclonal, no. A15693), anti-SDHA (Cell Signaling, no. 11998), anti-SDHB (Abcam, no. ab110413), anti-UQCRC2 (Aviva systems biology, no. OAAN01132), anti-MT-CO2 (ABclonal, no. A11154), anti-COX6B1 (ABclonal, no. A2228), anti-ATP5F1C (ABclonal, no. A15257), anti-ATP6VID (ABclonal, no. A12940), anti-ATP5F1A (ABclonal, no. A11217), anti-ACLY (ABclonal, no. A3719), anti-IDH3A (ABclonal, no. A14650), anti-DLD (ABclonal, no. A13296), anti-ACO2 (ABclonal, no. A3716), anti-MDH2 (ABclonal, no. A13516), Incubation:Article Title: Long-Term Effects of Radiation Therapy on Cerebral Microvessel Proteome: A Six Month Post-Exposure Analysis Article Snippet: Equal amounts of protein (5–10 μg) from control and irradiated groups were separated on NuPAGE 4% to 12% Bis-Tris gels (Life Technologies) and transferred to polyvinylidene difluoride (PVDF) membranes using the Mini-PROTEAN 3 blotting system (Bio-Rad). .. Membranes were stained with Ponceau S (Cell Signaling #59803S) to confirm protein transfer, washed in TBS with Tween (TBST), and blocked with 3% BSA (RPI Research #9048–46–8) or Starting Block Blocking Buffer (Thermo Fisher Scientific #37538) for 2 h. Membranes were incubated overnight at 4 °C with primary antibodies, including anti-NDUFB8 (Abcam, no. ab110413), anti-NDUFA11 (ABclonal, no. A16239), anti-NDUFA4 (ABclonal, no. A15693), anti-SDHA (Cell Signaling, no. 11998), anti-SDHB (Abcam, no. ab110413), anti-UQCRC2 (Aviva systems biology, no. OAAN01132), anti-MT-CO2 (ABclonal, no. A11154), anti-COX6B1 (ABclonal, no. A2228), anti-ATP5F1C (ABclonal, no. A15257), anti-ATP6VID (ABclonal, no. A12940), anti-ATP5F1A (ABclonal, no. A11217), anti-ACLY (ABclonal, no. A3719), anti-IDH3A (ABclonal, no. A14650), anti-DLD (ABclonal, no. A13296), anti-ACO2 (ABclonal, no. A3716), anti-MDH2 (ABclonal, no. A13516), Article Title: Long-Term Effects of Radiation Therapy on Cerebral Microvessel Proteome: A Six-Month Post-Exposure Analysis Article Snippet: Membranes were stained with Ponceau S (Cell Signaling #59803S) to confirm protein transfer, washed in TBS with TweenTM (TBST), and blocked with 3% BSA (RPI Research #9048-46-8) or Starting BlockTM Blocking Buffer (Thermo Fisher Scientific #37538) for 2 hours. .. Membranes were incubated overnight at 4°C with primary antibodies, including anti-NDUFB8 (Abcam, no. ab110413), anti-NDUFA11 (ABclonal, no. A16239), anti-NDUFA4 (ABclonal, no. A15693), anti-SDHA (Cell Signaling, no. 11998), anti-SDHB (Abcam, no. ab110413), anti-UQCRC2 (Aviva systems biology, no. OAAN01132), anti-MT-CO2 (ABclonal, no. A11154), anti-COX6B1 (ABclonal, no. A2228), anti-ATP5F1C (ABclonal, no. A15257), anti-ATP6VID (ABclonal, no. A12940), anti-ATP5F1A (ABclonal, no. A11217), anti-ACLY (ABclonal, no. A3719), anti-IDH3A (ABclonal, no. A14650), anti-DLD (ABclonal, no. A13296), anti-ACO2 (ABclonal, no. A3716), anti-MDH2 (ABclonal, no. A13516), Western Blot:Article Title: The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma. Article Snippet: Renal cell carcinoma (RCC) is one of the most common malignancies worldwide, and metabolic reprogramming has a profound effect on RCC tumorigenesis. mTORC1 inhibitors are widely used in RCC treatment, yet some types of RCC cells are resistant to these compounds.. Thus, clarification of the metabolic mechanism of mTORC1 inhibitors and exploration of new therapeutic approaches are urgently needed.. In this study, we found that the mTORC1 pathway was hyperactive in RCC. Article Title: Glycolysis Aids in Human Lens Epithelial Cells’ Adaptation to Hypoxia Article Snippet: The data were analysed using Image Lab software (version 6.1; Hong Kong Bio-Rad). .. The following antibodies were used for immunoblots: anti-β-actin (HRP-60008, Proteintech, Rosemont, IL, USA), anti-HK1 (2024, Cell Signaling Technology (CST), Danvers, MA, USA), anti-HK2 (sc-374091, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-PGK1 (sc-130335, Santa Cruz Biotechnology), Article Title: Glycolysis Aids in Human Lens Epithelial Cells' Adaptation to Hypoxia. Article Snippet: The data were analysed using Image Lab software (version 6.1; Hong Kong Bio-Rad). .. The following antibodies were used for immunoblots: anti-β-actin (HRP-60008, Proteintech, Rosemont, IL, USA), anti-HK1 (2024, Cell Signaling Technology (CST), Danvers, MA, USA), anti-HK2 (sc-374091, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-PGK1 (sc-130335, Santa Cruz Biotechnology), other:Article Title: Tanshinone I reprograms glycolysis metabolism to regulate histone H3 lysine 18 lactylation (H3K18la) and inhibits cancer cell growth in ovarian cancer. Article Snippet: The anti-HK2 (# 2867S), anti-PFK (# 8164S), anti-LDHA (# 3582S), anti-ENO2 (# 65162S), anti-FOXK2 (# 12008S), anti-FOXK1 (# 12025S), anti-GranzB (#44153), anti-FOXP3 (#12653), anti-ARG1 (#93668), anti-iNOS (#2982), anti-Histone H3 (# 4499T) and Tubulin (# 2144S) were purchased from cell Signaling Technology, Inc. H3K9lac (PTM-1419RM), H3K14lac (PTM-1414RM), H3K18lac (PTM-1406RM), Histone 3 and tubulin were purchased from PTM Biolabs, Inc. |